SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE

1 . Solid pharmaceutical preparation with delayed release, comprising:

a. at least one pharmaceutically active ingredient;

b. polyvinylpyrrolidone and/or a polyvinylpyrrolidone derivative with a K value of at least 17; and,

c. at least one filler.

2 . Solid pharmaceutical preparation according to claim 1 , comprising from 10 to 50% by weight of polyvinylpyrrolidone.

3 . Solid pharmaceutical preparation according to claim 1 , additionally comprising a disintegrant.

4 . Solid pharmaceutical preparation according to claim 3 , comprising the disintegrant in amounts of up to 5% (m/m).

5 . Solid pharmaceutical preparation according to claim 1 , wherein the active ingredient is a depsipeptide.

6 . Solid pharmaceutical preparation according to claim 5 , wherein the depsipeptide is emodepside.

7 . Solid pharmaceutical preparation according to claim 6 , further comprising praziquantel.

8 . Solid pharmaceutical preparation according to claims 1 , wherein the active ingredient is an analgesic.

9 . Solid pharmaceutical preparation according to claim 8 , wherein the analgesic is metamizole.

10 . Solid pharmaceutical preparation according to claims 1 , wherein the active ingredient is a macrocyclic lactone.

11 . Solid pharmaceutical preparation according to claim 10 , wherein the macrocyclic lactone is ivermectin.

12 . Solid pharmaceutical preparation according to claims 1 , wherein the active ingredient is a pharmacologically acceptable phosphonic acid derivative.

13 . Solid pharmaceutical preparation according to claim 12 , wherein the phosphonic acid derivative is butaphosphan.

14 . Solid pharmaceutical preparation according to claim 1 , characterized in that it releases 80% of the active ingredient in the paddle test of the US Pharmacopeia at 37° C. and 75 revolutions per minute under sink conditions within 1 to 6 hours.